Lv4
510 积分 2024-09-05 加入
Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
1天前
待确认
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
1天前
待确认
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
1天前
已完结
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
1个月前
已完结
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
1个月前
已完结
Semaglutide for the treatment of obesity
2个月前
已完结
272-OR: Weight Loss with Time-Restricted Feeding or Treatment with Obeticholic Acid/Semaglutide Combination Have a Different Impact on Nonalcoholic Steatohepatitis in Diet-Induced Obese Mice
2个月前
已关闭
GLP-1-based medications: Mechanisms involved in obesity treatment
2个月前
已完结
GLP-1 physiology informs the pharmacotherapy of obesity
2个月前
已完结
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
2个月前
已完结
皖公网安备34019202002308
